| Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964) |
|---|
| 11/01/2006 | CN1856506A Method for transplanting lymphohematopoietic cells into mammal |
| 11/01/2006 | CN1854300A Recombinant plasmid containing PON gene and its use |
| 11/01/2006 | CN1854157A Antibodies to insulin-like growth factor i receptor |
| 11/01/2006 | CN1853731A Use of staphylococcal enterotoxin A gene and its coded protein |
| 11/01/2006 | CN1853730A Modified cytokines for use in cancer therapy |
| 10/31/2006 | US7129337 Hepatitis C virus (HCV) polynucleic acid of given nucleotide sequence unique to at least one of the new HCV subtypes 7,9,10 OR 11, OR TO SUBTYPES 1D, 1E, 1F, 1G, 2E, 2F, 2G, 2H, 2I, 2K, 2L,3G,4K OR 4M; producing recombinant polypeptide |
| 10/31/2006 | US7129223 Inhibition of SARS-associated coronavirus (SCoV) infection and replication by RNA interference |
| 10/31/2006 | US7129222 Immunomodulatory formulations and methods for use thereof |
| 10/31/2006 | US7129207 Nucleotide sequences coding polypeptide for use in the diagnosis, prevention and treatment of cancer, psoriasis and nervous system disorders |
| 10/31/2006 | US7129074 Nucleoside triphosphate diphosphohydrolase (NTPDase 8) and uses thereof |
| 10/31/2006 | US7129061 Pure polypeptide containing a fragment capable of binding to and inducing apoptosis in a carcinoma cell; Tumor Necrosis Factor Related ligand or "TRELL", a polypeptide which is a member of the Tumor Necrosis Factor Family |
| 10/31/2006 | US7129040 identification, on human chromosome 10, of a tumor suppressor gene. Defects in this gene are associated with the development of cancers, such as gliomas |
| 10/31/2006 | US7129037 Delivering antigen to dendritic cells by contacting dendritic cells with apopototic cells expressing an antigen to allow antigen to be internalized by the dendritic cells, and wherein apoptotic cells have been induced in vitro to become apoptotic |
| 10/31/2006 | US7129034 Culturing stem cell with fibroblast growth factor and epidermal growth factor |
| 10/31/2006 | US7128916 Bacteriophage-mediated immunisation |
| 10/31/2006 | US7128906 T1 receptor-like ligand II and uses thereof |
| 10/31/2006 | CA2236925C Microencapsulated dna for vaccination and gene therapy |
| 10/26/2006 | WO2006113679A2 Delivery of sirna by neutral lipid compositions |
| 10/26/2006 | WO2006113579A2 Tumor inhibition by modulating sprouty expression or activity |
| 10/26/2006 | WO2006113470A2 Cancer treatment by combined inhibition of proteasome and telomerase activities |
| 10/26/2006 | WO2006113431A2 Dual functional oligonucleotides for use as anti-viral agents |
| 10/26/2006 | WO2006113246A2 Small activating rna molecules and methods of use |
| 10/26/2006 | WO2006112869A2 Modulation of cytokine signaling regulators and applications for immunotherapy |
| 10/26/2006 | WO2006112739A1 Novel peptides and methods for the treatment of inflammatory disorders |
| 10/26/2006 | WO2006112456A1 Perkinson disease-related gene grk5 and use thereof |
| 10/26/2006 | WO2006112401A1 Composition for treatment of cancer |
| 10/26/2006 | WO2006112239A1 hTERT GENE EXPRESSION REGULATORY GENE |
| 10/26/2006 | WO2006111998A1 Recombinant adenoviral vector for the expression of mdm family proteins and uses thereof |
| 10/26/2006 | WO2006111596A1 Use of hdac6 protein tubulin deacetylase activity agonist compounds in the preparation of pharmaceutical compositions, said pharmaceutical compositions and applications of same in the treatment of viral infections |
| 10/26/2006 | WO2006076343A8 Mycobacteria expressing hiv-1 and malaria antigens |
| 10/26/2006 | WO2006069306A3 A knockout mouse for the tumor suppressor gene anx7 |
| 10/26/2006 | WO2006060598A3 RNA INTERFERENCE MEDIATED INHIBITION OF INTERLEUKIN AND INTERLEUKIN RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| 10/26/2006 | WO2006058038A3 In vitro and in vivo silencing of human c-myc oncogene expression by poly-dnp-rna |
| 10/26/2006 | WO2005060542A3 Use of serum amyloid a gene in diagnosis and treatment of glaucoma and identification of anti-glaucoma agents |
| 10/26/2006 | US20060242725 for importing nucleic acids, such as DNA, into the nuclei of osteoblast lineage cells (the bone forming cells of the skeleton) |
| 10/26/2006 | US20060242719 Nucleotide sequences of shrimp beta-actin and actin promoters and their use in gentic transformation technology |
| 10/26/2006 | US20060241290 recombinant or monoclonal antibodies comprising the antigen-binding fragments specific for polypeptides, used for treating the effects of stroke, hypoxia and/or ischemia |
| 10/26/2006 | US20060241076 Modified oligoribonucleotide analogs with enhanced immunostimulatory activity |
| 10/26/2006 | US20060241075 Moderating Desmoglein gene expression |
| 10/26/2006 | US20060241074 Methods for treatment of pain |
| 10/26/2006 | US20060241073 Means and methods for counteracting fatty acid accumulation |
| 10/26/2006 | US20060241072 Oligomeric compounds for use in gene modulation |
| 10/26/2006 | US20060241071 Quaternary ammonium compound having ester and/or amide groups; cationic amphiphilic molecule or macromolecule that transforms from a cationic entity to an anionic, neutral, or zwitterionic entity by a chemical, photochemical, or biological reaction and its use for delivery of nucleic acids |
| 10/26/2006 | US20060241070 Antisense oligonucleotides directed to ribonucleotide reductase r2 and uses thereof in the treament of cancer |
| 10/26/2006 | US20060241069 Treatment of hyperproliferative disease |
| 10/26/2006 | US20060241068 Cardiac failure, cardiomegaly, myocarditis, cardiomyopathy, arteriosclerosis, arteriosclerosis obliterans, or ischemic heart disease |
| 10/26/2006 | US20060241067 Methods For inhibiting angiogenesis, cell migration, cell adhesion, and cell survival |
| 10/26/2006 | US20060241066 Decoy composition for treating and preventing inflammatory disease |
| 10/26/2006 | US20060241036 Soluble human interleukin 18 receptor-alpha, method of assaying the same, assay kit and medicinal composition |
| 10/26/2006 | US20060241035 Use of dg153 secreted protein products for preventing and treating pancreatic disease and/or obesity and/or metabolic syndrome |
| 10/26/2006 | US20060241034 Means for preventing and treating cellular death and their biological applications |
| 10/26/2006 | US20060241033 Markers for pre-cancer and cancer calls and the method to interfere with cell proliferation therein |
| 10/26/2006 | US20060240559 5-hydroxytryptamine transporter gene polymorphisms |
| 10/26/2006 | US20060240553 Cultures of human CNS neural stem cells |
| 10/26/2006 | US20060240520 monitoring the efficacy of a BAFF-R (a B-cell activating factor belonging to the Tumor Necrosis Factor family) antagonist in the treatment of a disease or disorder associated with aberrant levels of B-cells or B-cell activity |
| 10/26/2006 | US20060240519 Novel receptor nucleic acids and polypeptides |
| 10/26/2006 | US20060240518 polypeptides related to a receptor to BAFF (a B-cell activating factor belonging to the Tumor Necrosis Factor family, which is associated with theexpression of B-cells and immunoglobulins); this receptor can be employed in the treatment of cancers, lymphomas, autoimmune diseases related to B-cells |
| 10/26/2006 | US20060240517 Novel receptor nucleic acids and polypeptides |
| 10/26/2006 | US20060240500 Diagnosis of kidney damage and protection against same |
| 10/26/2006 | US20060240459 ClCKb mutation as a diagnostic and therapeutical target |
| 10/26/2006 | US20060240422 Caspase 10 as target for monitoring and treatment of diseases |
| 10/26/2006 | US20060240417 Agent controlling the apoptosis induction by p73 |
| 10/26/2006 | US20060240414 Genetically engineered glutaminase and its use in antiviral and anticancer therapy |
| 10/26/2006 | US20060240114 Drug for treating hemophilia and method of treating hemophilia using the same |
| 10/26/2006 | US20060240093 silencing gene expression by delivering nucleic acid-lipid particles comprising a siRNA molecule to a cell; hepatitis |
| 10/26/2006 | US20060240092 Polymeric micelles for drug delivery |
| 10/26/2006 | US20060240088 Caged ligands and uses thereof |
| 10/26/2006 | US20060240070 Delivery of highly lipophilic agents via medical devices |
| 10/26/2006 | US20060240022 Factor involved in metastasis and uses thereof |
| 10/26/2006 | US20060240019 Antagonists of HMG1 for treating inflammatory conditions |
| 10/26/2006 | US20060240013 Diagnostics and therapeutics for diseases associated with bile acid g-protein-coupled receptor 37 (bg37) |
| 10/26/2006 | US20060239999 Preventive and/or therapeutic drugs for asthma |
| 10/26/2006 | US20060239991 polypeptide has the biological activity of methionyl tRNA synthetase; for the protection against bacterial infections |
| 10/26/2006 | US20060239990 Protein Arginine N-Methyltransferase 2 (PRMT-2) |
| 10/26/2006 | US20060239985 Method of preparing cell for transplantation |
| 10/26/2006 | US20060239984 Promoter to il-18bp, its preparation and use |
| 10/26/2006 | US20060239980 Cartilage-derived stem cells and applications thereof |
| 10/26/2006 | US20060239976 75K RNA regulated transcription |
| 10/26/2006 | US20060239975 Methods for treating cancers and restenosis with p21 |
| 10/26/2006 | US20060239974 Enhancing cell migration by increasing telomerase activity |
| 10/26/2006 | US20060239973 Methods and compositions for the treatment of ocular diseases |
| 10/26/2006 | US20060239972 Adiponectin gene therapy |
| 10/26/2006 | US20060239971 Vectors for regulating gene expression |
| 10/26/2006 | US20060239970 Herpesvirus amplicon particles |
| 10/26/2006 | US20060239969 Isolated nucleic acid molecule; enhancing immunity to the protein product expressed by the HER2/neu tumor-associated antigen |
| 10/26/2006 | US20060239968 method of delivering agent to prostate cancer tissue comprising obtaining peptide that selectively binds to prostate cancer tissue, where peptide is less than 100 amino acids in length and includes prostate cancer targeting motif having disclosed amino acid sequence; peptide is attached to target agent |
| 10/26/2006 | US20060239967 Oncolytic virus replicating selectively in tumor cells |
| 10/26/2006 | US20060239966 In vivo gene therapy of parkinson's disease |
| 10/26/2006 | CA2604515A1 Toll-like receptor 14 (tlr14 ) and use thereof |
| 10/26/2006 | CA2574603A1 Oligonucleotides comprising a ligand tethered to a modified or non-natural nucleobase |
| 10/26/2006 | CA2574572A1 Modulation of cytokine signaling regulators and applications for immunotherapy |
| 10/25/2006 | EP1715064A1 Nucleotide sequences derived from the genomes of the retroviruses HIV-1, HIV-2 and SIV, and their application to the amplification of these viral genomes and to the in vitro diagnosis of infections resulting from these viruses |
| 10/25/2006 | EP1715052A1 Composition and method for elevating gene transfer efficiency |
| 10/25/2006 | EP1715051A1 Gene construct systems for isolating a pure population of cells of a single cell type |
| 10/25/2006 | EP1715043A2 Compounds for immunotherapy and diagnosis of colon cancer and methods for their use |
| 10/25/2006 | EP1715040A2 Zinc finger binding domains for GNN |
| 10/25/2006 | EP1715038A1 Antibody targeting osteoclast-associated protein |
| 10/25/2006 | EP1715035A2 Synthetic polynucleotides encoding lysyl oxidase |
| 10/25/2006 | EP1715033A1 Medium for preparing feeder cells for embryonic stem cells and feeder cells |
| 10/25/2006 | EP1714970A1 Use of inhibitors of RNAse A-family enzymes for stabilizing oligonucleotides having RNA interfering activity |